AR070177A1 - COMPOSICIONES BACTERIANAS QUE COMPRENDEN PROTEíNAS PERTENECIENTES AL GRUPO DE RECEPTORES DE RECONOCIMIENTO DE PATRONES (PRR) QUE PRESENTAN UN DOMINIO DE REPETICIoN DE LEUCINA (RRL) - Google Patents

COMPOSICIONES BACTERIANAS QUE COMPRENDEN PROTEíNAS PERTENECIENTES AL GRUPO DE RECEPTORES DE RECONOCIMIENTO DE PATRONES (PRR) QUE PRESENTAN UN DOMINIO DE REPETICIoN DE LEUCINA (RRL)

Info

Publication number
AR070177A1
AR070177A1 ARP090100122A ARP090100122A AR070177A1 AR 070177 A1 AR070177 A1 AR 070177A1 AR P090100122 A ARP090100122 A AR P090100122A AR P090100122 A ARP090100122 A AR P090100122A AR 070177 A1 AR070177 A1 AR 070177A1
Authority
AR
Argentina
Prior art keywords
rrl
prr
presenting
group
pattern recognition
Prior art date
Application number
ARP090100122A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR070177A1 publication Critical patent/AR070177A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una proteína aislada para utilizarse como un agente antimicrobiano, que comprende una pluralidad de dominios RRL (repeticion rica en leucina), cada dominio RRL independientemente comprende una secuencia de aminoácidos de la Formula: (F1LxxLxL(xxZ)yF2) en donde: F1 y F2 son, independientemente, una secuencia de aminoácidos contigua de entre 1 y 30 residuos; x puede ser cualquier aminoácido; L puede ser Leu, Ile, Val o Phe; Z puede ser NxL o CxxL; N es Asn, Thr, Ser o Cys; C es Cys o Ser; y Y=0 o 1. Las composiciones con dicha proteína son utiles para tratar en el ser humano una enfermedad microbiana gastrointestinal.
ARP090100122A 2008-01-15 2009-01-15 COMPOSICIONES BACTERIANAS QUE COMPRENDEN PROTEíNAS PERTENECIENTES AL GRUPO DE RECEPTORES DE RECONOCIMIENTO DE PATRONES (PRR) QUE PRESENTAN UN DOMINIO DE REPETICIoN DE LEUCINA (RRL) AR070177A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08150290 2008-01-15

Publications (1)

Publication Number Publication Date
AR070177A1 true AR070177A1 (es) 2010-03-17

Family

ID=39495862

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100122A AR070177A1 (es) 2008-01-15 2009-01-15 COMPOSICIONES BACTERIANAS QUE COMPRENDEN PROTEíNAS PERTENECIENTES AL GRUPO DE RECEPTORES DE RECONOCIMIENTO DE PATRONES (PRR) QUE PRESENTAN UN DOMINIO DE REPETICIoN DE LEUCINA (RRL)

Country Status (15)

Country Link
US (1) US20100286027A1 (es)
EP (1) EP2242763A1 (es)
JP (1) JP2011509966A (es)
KR (1) KR20100116612A (es)
CN (1) CN102037006A (es)
AR (1) AR070177A1 (es)
AU (1) AU2009204842A1 (es)
BR (1) BRPI0906517A2 (es)
CA (1) CA2711972A1 (es)
CL (1) CL2009000065A1 (es)
EA (1) EA201001138A1 (es)
MX (1) MX2010007727A (es)
PE (1) PE20091334A1 (es)
TW (1) TW200936155A (es)
WO (1) WO2009090168A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5732449B2 (ja) * 2010-03-10 2015-06-10 国立大学法人浜松医科大学 高病原性口腔細菌による腸炎誘発原因分子の産生とその高感度検出法
US9688726B2 (en) 2011-12-19 2017-06-27 Shanghai First People's Hospital Small molecule polypeptide for inhibiting inflammation
US11369657B2 (en) 2011-12-19 2022-06-28 Shanghai First People's Hospital Small molecule polypeptide for preventing and restraining inflammation and application of same
CN105176882B (zh) * 2015-10-17 2018-09-21 福清市默克兽医院 一种牛摩氏摩根菌性关节炎灭活疫苗及其制备方法
CN114671945A (zh) * 2022-01-14 2022-06-28 长沙学院 一种草鱼细菌小肽识别受体及制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040293A (en) * 1996-11-06 2000-03-21 The Regents Of The University Of California Clavanins

Also Published As

Publication number Publication date
EP2242763A1 (en) 2010-10-27
KR20100116612A (ko) 2010-11-01
JP2011509966A (ja) 2011-03-31
AU2009204842A1 (en) 2009-07-23
EA201001138A1 (ru) 2011-02-28
WO2009090168A1 (en) 2009-07-23
PE20091334A1 (es) 2009-09-18
CA2711972A1 (en) 2009-07-23
TW200936155A (en) 2009-09-01
BRPI0906517A2 (pt) 2019-09-24
CL2009000065A1 (es) 2009-11-06
MX2010007727A (es) 2010-10-26
CN102037006A (zh) 2011-04-27
US20100286027A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
CL2018000537A1 (es) Anticuerpo anti-factor d del complemento; polinucleótido codificante; vector que comprende dicho polinucleótido; célula húesped que comprende dicho vector; método de fabricación de anticuerpo; composición farmacéutica que lo comprende; uso del anticuerpo para tratar trastornos inflamatorios o trastornos oculares (divisional de cl 1001-2009).
CO2020009625A2 (es) Inhibidor de fap
AR070177A1 (es) COMPOSICIONES BACTERIANAS QUE COMPRENDEN PROTEíNAS PERTENECIENTES AL GRUPO DE RECEPTORES DE RECONOCIMIENTO DE PATRONES (PRR) QUE PRESENTAN UN DOMINIO DE REPETICIoN DE LEUCINA (RRL)
BR112022016220A2 (pt) Polipeptídeos, composições e seu uso para tratar ou limitar o desenvolvimento de uma infecção
CL2013001673A1 (es) Composicion acuosa que comprende aproximadamente 18% p/v de concentracion, donde al menos el 95% de las proteinas son igg; metodo mejorado para preparar dicha composición.
WO2015138907A3 (en) Hybrid immunoglobulin containing non-peptidyl linkage
ECSP11011297A (es) Proteinas ligadoras il-17
PE20130588A1 (es) Hepcidina, antagonistas de la hepcidina y metodos de uso
CR20170070A (es) Composición, método y preparación del ácido biliar sintético
BRPI0607883A2 (pt) método para obter material celular prontamente disponìvel derivado de sangue periférico e uma composição do referido material celular
WO2008061208A3 (en) Arylsulfonamide compounds
BR112013002831A2 (pt) anticorpos direcionados contra a il-17
CO2022003218A2 (es) Péptido q-er
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
BRPI0608277A2 (pt) método e composição para o reparo de tecidos do coração
CR20110462A (es) Anticuerpos contra la proteína tweak humana y usos de los mismos
AR073810A1 (es) Polipeptidos que tienen actividad antimicrobiana
BR112018014175A2 (pt) composição antibacteriana e método para tratar infecções estafilocócicas com a composição antibacteriana
AR031924A1 (es) Anticuerpos anti-cd28 silenciados y el uso de estos
NZ594481A (en) Truncated cystine-knot proteins
BR112012010964A2 (pt) uso de composições contendo luteína para melhorar certos aspectos da memória
BR112012011894A2 (pt) "composição de enxerto para a regeneração de tecido neural, método de produção e usos destes".
BRPI0607882A2 (pt) método e composição para tratamento de diabetes
CL2004000535A1 (es) Composicion farmaceutica que comprende rapamicina o un derivado de rapamicina y pimecrolimus; y su uso para el tratamiento de enfermedad inflamatoria del intestino.
AR073967A1 (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen al mismo

Legal Events

Date Code Title Description
FB Suspension of granting procedure